Trials / Completed
CompletedNCT02572687
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC).
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Non-Small Cell Lung Cancer
- Hepatocellular Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
| DRUG | MEDI4736 | Administered IV |
Timeline
- Start date
- 2016-02-19
- Primary completion
- 2018-03-27
- Completion
- 2021-01-13
- First posted
- 2015-10-09
- Last updated
- 2021-01-20
Locations
28 sites across 8 countries: United States, France, Germany, Israel, Italy, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT02572687. Inclusion in this directory is not an endorsement.